BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/12/2020 11:28:25 AM | Browse: 1771 | Download: 2980
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 51067
Country France
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Observational Study
Article Title FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Manuscript Source Unsolicited Manuscript
All Author List Angélique Vienot, Hortense Chevalier, Clément Bolognini, Elisabeta Gherga, Elodie Klajer, Aurélia Meurisse, Marine Jary, Stefano Kim, Christelle d'Engremont, Thierry Nguyen, Fabien Calcagno, Hamadi Almotlak, Francine Fein, Meher Nasri, Syrine Abdeljaoued, Anthony Turpin, Christophe Borg and Dewi Vernerey
ORCID
Author(s) ORCID Number
Angélique Vienot http://orcid.org/0000-0002-0381-7601
Hortense Chevalier http://orcid.org/0000-0001-8523-4030
Clément Bolognini http://orcid.org/0000-0001-5002-7170
Elisabeta Gherga http://orcid.org/0000-0001-7131-6596
Elodie Klajer http://orcid.org/0000-0002-4226-6339
Aurélia Meurisse http://orcid.org/0000-0002-1210-5163
Marine Jary http://orcid.org/0000-0002-2866-7195
Stefano Kim http://orcid.org/0000-0003-2851-7119
Christelle d'Engremont http://orcid.org/0000-0002-1888-4567
Thierry Nguyen http://orcid.org/0000-0002-9758-9485
Fabien Calcagno http://orcid.org/0000-0003-1455-3776
Hamadi Almotlak http://orcid.org/0000-0001-7290-0700
Francine Fein http://orcid.org/0000-0003-1649-516X
Meher Nasri http://orcid.org/0000-0002-9848-0174
Syrine Abdeljaoued http://orcid.org/0000-0002-2423-5328
Anthony Turpin http://orcid.org/0000-0002-2282-0101
Christophe Borg http://orcid.org/0000-0001-6161-0169
Dewi Vernerey http://orcid.org/0000-0001-6399-926X
Funding Agency and Grant Number
Corresponding Author Angélique Vienot, MD, Doctor, Doctor, Department of Medical Oncology, Besançon University Hospital, 3 Boulevard Alexandre Fleming, Besançon F-25030, France. angelique.vienot@gmail.com
Key Words Advanced pancreatic cancer; First-line chemotherapy; FOLFOXIRI; FOLFIRINOX; Propensity score; Cohort study
Core Tip This is the first study to compare FOLFOXIRI and FOLFIRINOX regimens head-to-head, to assess whether FOLFOXIRI contributes to better a balance of the toxicity/efficacy ratio in advanced pancreatic ductal adenocarcinoma. These findings do not suggest any therapeutic benefit of FOLFOXIRI compared to FOLFIRINOX in first-line chemotherapy. These results show that additional evaluation is not warranted in future clinical trials. FOLFIRINOX chemotherapy remains the standard of care first-line therapy in metastatic pancreatic ductal adenocarcinoma. Interestingly, the low hematological toxicity rates in both regimens underscore the interest of prophylactic administration of hematopoietic growth factors in routine use after each polychemotherapy cycle.
Publish Date 2020-03-12 11:28
Citation Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346
URL https://www.wjgnet.com/1948-5204/full/v12/i3/332.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i3.332
Full Article (PDF) WJGO-12-332.pdf
Full Article (Word) WJGO-12-332.docx